AKE Stock Analysis: Arkema | PA
Specialty Chemicals | PA, France | Market Cap: 4.230m EUR | 12M Return: -8.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.6M
EPS Trend: -89.3%
Qual. Beats: 0
Rev. Trend: -80.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arkema S.A. (AKE) is a French specialty materials manufacturer operating across Europe, North America, and Asia, with a presence in approximately 60 countries. The company is structured around three business segments: Adhesive Solutions, Advanced Materials, and Coating Solutions, alongside an Intermediates segment. Its product portfolio spans high-performance polymers (such as specialty polyamides, PVDF, and polyimides), performance additives, acrylics, coating resins, and fluorogases. End-markets served include construction, automotive, packaging, electronics, oil and gas, renewable energy, water treatment, and 3D printing.
The company was incorporated in 2003 and is headquartered in Puteaux, France. Arkema is listed on Euronext Paris and classified within the Diversified Chemicals sub-industry of the Materials sector. Its business model is anchored in specialty rather than commodity chemistry, focusing on high-value applications such as lightweighting, bio-based products, recycling solutions, and new energy technologies, which typically command higher margins and provide resilience against raw material price volatility.
- PVDF and battery materials demand accelerates Advanced Materials revenue growth
- European energy costs and raw material volatility pressure Intermediates segment margins
- Bostik integration expands Adhesive Solutions margins in construction renovation
| Net Income: 41.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.00 > 1.0 |
| NWC/Revenue: 30.28% < 20% (prev 27.12%; Δ 3.16% < -1%) |
| CFO/TA 0.07 > 3% & CFO 983.6m > Net Income 41.3m |
| Net Debt (3.70b) to EBITDA (1.12b): 3.32 < 3 |
| Current Ratio: 2.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (75.9m) vs 12m ago -0.08% < -2% |
| Gross Margin: 17.56% > 18% (prev 19.95%; Δ -2.39% > 0.5%) |
| Asset Turnover: 62.19% > 50% (prev 67.01%; Δ -4.82% > 0%) |
| Interest Coverage Ratio: 2.26 > 6 (EBIT TTM 293.7m / Interest Expense TTM 130.0m) |
| A: 0.19 (Total Current Assets 4.84b - Total Current Liabilities 2.15b) / Total Assets 14.2b |
| B: 0.31 (Retained Earnings 4.41b / Total Assets 14.2b) |
| C: 0.02 (EBIT TTM 293.7m / Avg Total Assets 14.3b) |
| D: 0.78 (Book Value of Equity 6.16b / Total Liabilities 7.88b) |
| Altman-Z'' = 3.21 = A |
| DSRI: 0.92 (Receivables 1.48b/1.73b, Revenue 8.87b/9.58b) |
| GMI: 1.14 (GM 19.95% / 17.56%) |
| AQI: 0.94 (AQ_t 0.38 / AQ_t-1 0.41) |
| SGI: 0.93 (Revenue 8.87b / 9.58b) |
| TATA: -0.07 (NI 41.3m - CFO 983.6m) / TA 14.2b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at EUR 54.65 with a total of 175,413 shares traded. Over the past week, the price has changed by -1.62%, over one month by -5.53%, over three months by -2.59% and over the past year by -8.65%.
Current recommended Stop Loss: 52.30 (which is 4.3% or 1.5 ATR below the current price).
Arkema has no consensus analysts rating.
P/E Trailing = 243.0435
P/E Forward = 12.2549
P/S = 0.477
P/B = 0.6157
P/EG = 0.4673
Revenue TTM = 8.87b EUR
EBIT TTM = 293.7m EUR
EBITDA TTM = 1.12b EUR
Long Term Debt = 3.51b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 465.3m EUR (from shortTermDebt, last quarter)
Debt = 5.43b EUR (from shortLongTermDebtTotal, last quarter) + Leases 358.0m
Net Debt = 3.70b EUR (calculated: Debt 5.43b - CCE 1.73b)
Enterprise Value = 7.93b EUR (4.23b + Debt 5.43b - CCE 1.73b)
Interest Coverage Ratio = 2.26 (Ebit TTM 293.7m / Interest Expense TTM 130.0m)
EV/FCF = 19.83x (Enterprise Value 7.93b / FCF TTM 400.0m)
FCF Yield = 5.04% (FCF TTM 400.0m / Enterprise Value 7.93b)
FCF Margin = 4.51% (FCF TTM 400.0m / Revenue TTM 8.87b)
Net Margin = 0.47% (Net Income TTM 41.3m / Revenue TTM 8.87b)
Gross Margin = 17.56% ((Revenue TTM 8.87b - Cost of Revenue TTM 7.31b) / Revenue TTM)
Gross Margin QoQ = 17.60% (prev 14.82%)
Tobins Q-Ratio = 0.56 (Enterprise Value 7.93b / Total Assets 14.2b)
Interest Expense / Debt = 2.39% (Interest Expense 130.0m / Debt 5.43b)
Taxrate = 37.19% (16.7m / 44.9m)
NOPAT = 184.5m (EBIT 293.7m * (1 - 37.19%))
Current Ratio = 2.25 (Total Current Assets 4.84b / Total Current Liabilities 2.15b)
Debt / Equity = 0.88 (Debt 5.43b / totalStockholderEquity, last quarter 6.16b)
Debt / EBITDA = 3.32 (Net Debt 3.70b / EBITDA 1.12b)
Debt / FCF = 9.26 (Net Debt 3.70b / FCF TTM 400.0m)
Total Stockholder Equity = 6.66b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.29% (Net Income 41.3m / Total Assets 14.2b)
RoE = 0.62% (Net Income TTM 41.3m / Total Stockholder Equity 6.66b)
RoCE = 2.89% (EBIT 293.7m / Capital Employed (Equity 6.66b + L.T.Debt 3.51b))
RoIC = 1.53% (NOPAT 184.5m / Invested Capital 12.1b)
WACC = 4.36% (E(4.23b)/V(9.66b) * Re(8.02%) + D(5.43b)/V(9.66b) * Rd(2.39%) * (1-Tc(0.37)))
Discount Rate = 8.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.47 | Cagr: 0.11%
[DCF] Terminal Value 77.97% ; FCFF base≈343.6m ; Y1≈393.9m ; Y5≈579.7m
[DCF] Fair Price = 66.35 (EV 8.72b - Net Debt 3.70b = Equity 5.02b / Shares 75.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -89.27 | EPS CAGR: -25.76% | SUE: 0.39 | # QB: 0
Revenue Correlation: -80.57 | Revenue CAGR: -3.56% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.61 | Chg30d=-1.45% | Revisions=-25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.38 | Chg30d=-1.03% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=4.61 | Chg30d=+0.11% | Revisions=-29% | GrowthEPS=+6.6% | GrowthRev=+0.8%
EPS next Year (2027-12-31): EPS=5.87 | Chg30d=+0.24% | Revisions=-29% | GrowthEPS=+27.5% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: -46% (up=2, down=8)